- 1 Title: Long-Term Impact of Molecular Epidemiology Shifts of Methicillin-resistant
- 2 Staphylococcus aureus on Severity and Mortality of Bloodstream Infection
- 3 Authors: Norihito Kaku<sup>a,b\*</sup>, Masaki Ishige<sup>b</sup>, Go Yasutake<sup>a,b</sup>, Daisuke Sasaki<sup>b</sup>, Kenji Ota<sup>a,b</sup>,
- 4 Fujiko Mitsumoto-Kaseida<sup>a,b</sup>, Kosuke Kosai<sup>a,b</sup>, Hiroo Hasegawa<sup>a,b</sup>, Koichi Izumikawa<sup>c</sup>, Hiroshi
- 5 Mukae<sup>d</sup>, Katsunori Yanagihara<sup>a,b</sup>
- <sup>a</sup>Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical
- 7 Sciences, Nagasaki City, Nagasaki, Japan 852-8501
- <sup>b</sup>Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki,
- 9 Japan 852-8501
- 10 <sup>c</sup>Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical
- 11 Sciences, Nagasaki City, Nagasaki, Japan 852-8501
- <sup>12</sup> <sup>d</sup>Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki,
- 13 Japan 852-8501
- 14 **\*Corresponding Author:** Norihito Kaku
- 15 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan 852-8501
- 16 Email: norihitk@gmail.com
- 17 Tel: +81-95-819-7574

## 18 Abstract

19 A 2019 nationwide study in Japan revealed the predominant methicillin-resistant Staphylococcus 20 aureus (MRSA) types in bloodstream infections (BSI) to be sequence type (ST)8-carrying 21 SCCmec type IV (ST8-MRSA-IV) and clonal complex 1-carrying SCCmec type IV (CC1-22 MRSA-IV). However, detailed patient characteristics and how these MRSA types evolve over 23 time remain largely unknown. In this long-term single-center study, MRSA strains isolated from 24 blood cultures at Nagasaki University Hospital from 2012 to 2019 were sequenced and analyzed. 25 Additionally, we compared the SCC*mec* types and patient characteristics identified in this study 26 with previous data from our hospital spanning 2003 to 2007 and 2008 to 2011. Over this 16-year 27 period, SCCmec type II decreased significantly from 79.2% to 15.5%, while type IV increased 28 from 18.2% to 65.5%. This shift in SCCmec types was associated with notable changes in 29 severity and outcomes; the sequential organ failure assessment (SOFA) score decreased from 5.8 30 to 3.1; in-hospital mortality declined from 39.8% to 15.5%. In contrast, no significant changes in 31 patient demographics, such as age, sex, or underlying diseases, were observed. Between 2012 32 and 2019, the major combinations of SCC*mec* type and sequence type were ST8-MRSA-IV, 33 ST8-MRSA-I, CC1-MRSA-IV, and ST5-MRSA-II. Additionally, ST8-MRSA-IV was divided 34 into CA-MRSA/J, t5071-ST8-MRSA-IV, and USA300-like clone based on the results of 35 molecular analysis. These major combinations showed similar drug resistance patterns, 36 molecular characteristics, and phylogenetic features to those identified in nationwide 37 surveillance. This study highlights the evolving nature of MRSA types in bloodstream infections, 38 correlating with improved patient outcomes over time. 39 **Keywords:** whole genome sequencing; Sepsis; methicillin-resistant *Staphylococcus aureus*; 40 Staphylococcal infections; mortality

41

## 42 Introduction

- 43 Bloodstream infection (BSI) is a severe condition that can lead to sepsis, a systemic
- 44 inflammatory response. Therefore, administering proper treatment as early as possible is crucial.
- 45 However, when drug-resistant bacteria cause BSI, appropriate treatment may be delayed.
- 46 Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common causative pathogen of
- 47 BSI.<sup>1,2</sup> In Japan and the USA, the New York/Japan clone, characterized by the presence of the
- 48 ST5 harboring SCCmec II island (ST5-MRSA-II) and multidrug resistance, was the predominant
- 49 MRSA strain.<sup>3</sup> However, our previous report revealed a decrease in SCC*mec* type II from 79.2%
- 50 between 2003 and 2007 to 44.9% between 2008 and 2011; conversely, SCC*mec* types I and IV
- 51 increased.<sup>4</sup> According to nationwide surveillance conducted in 2019, ST8 carrying SCC*mec* type

52 IV (ST8-MRSA-IV) and clonal complex 1 carrying SCCmec type IV (CC1-MRSA-IV) were the

- 53 predominant molecular types in BSI.<sup>5</sup> Additionally, ST8-MRSA-IV is subdivided into several
- 54 groups based on molecular characteristics.<sup>5</sup> However, owing to the limited number of MRSA
- strains detected at each facility during the surveillance, it remains undetermined whether similar
- trends are observed in individual facilities. Furthermore, the differences in the backgrounds of

57 patients infected with various MRSA types remain unknown.

58 Therefore, in this study, we aimed to investigate how the molecular epidemiological

59 characteristics of MRSA detected in BSIs at our hospital have changed since 2012 and whether

60 they align with the trends observed in the 2019 nationwide surveillance. We also investigated the

- 61 differences in drug-resistance genes, virulence genes, and patient characteristics, including
- 62 mortality, among the different MRSA types.
- 63
- 64

## 65 Materials and methods

## 66 Strain and data collection

Previously.<sup>4,6</sup> we used to collect MRSA strains detected in one or more blood cultures because 67 68 collecting more than two sets of blood cultures was not a common practice at our hospital. 69 However, collecting two or more sets of blood cultures has become more common since the 70 2010s. Therefore, in this study, we collected MRSA strains detected in two or more blood 71 cultures between January 2012 and December 2019 at Nagasaki University Hospital using the same inclusion criteria for nationwide surveillance.<sup>5</sup> Nagasaki University Hospital, a tertiary 72 medical institution with 874 beds, is located in Nagasaki Prefecture, the westernmost part of 73 Japan. We also collected information regarding blood culture collection location (outpatient or 74 75 inpatient), the day of hospitalization blood culture collection, antimicrobial use during the 30 76 days before the onset of BSI, initial antimicrobial regimens for BSI, mortality, and the details required to calculate the Charlson comorbidity index<sup>7</sup> and Sequential Organ Failure Assessment 77 (SOFA) score<sup>8</sup> from the medical records at Nagasaki University Hospital. 78 79 80 Antimicrobial susceptibility testing 81 We measured the minimum inhibitory concentrations (MICs) using broth microdilution testing 82 using a dry plate (Eiken, Tokyo, Japan), according to the manufacturer's instructions. 83 Antimicrobial susceptibility was determined according to the Clinical and Laboratory Standards 84 Institute guidelines (CLSI M100-Ed31) and the European Committee on Antimicrobial 85 Susceptibility Testing Version 11.0.

86 Whole-genome sequencing (WGS)

87 All procedures were performed according to the respective manufacturer's instructions. After 88 extracting the DNA from MRSA strains using a Quick-DNA Fungal/Bacterial Kit (ZYMO 89 RESEARCH, Irvine, CA, United States), we performed WGS on the MRSA strains isolated 90 between 2012 and 2015 using an Ion PGM HiQ View OT2 Kit (Thermo Fisher Scientific, 91 Waltham, MA, USA). Enriched samples were loaded onto an Ion 318 chip and sequenced using 92 an IonTorrent Personal Genome Analyzer with an Ion PGM HiQ View Sequencing Kit (Thermo 93 Fisher Scientific). DNA libraries were generated for Ion PGM using the Ion Xpress Plus 94 Fragment Library Kit (4471269; Thermo Fisher Scientific). We performed WGS for the MRSA 95 strains isolated between 2016 and 2019 using the MiSeq system (Illumina, San Diego, CA, 96 United States) and MiSeq Reagent kit v3 (600 cycles) (Illumina). We also performed WGS for MRSA strains isolated between 2012 and 2015, which needed to be retested using the MiSeq 97 98 system. We generated DNA libraries for the Miseq system using Invitrogen (Waltham, MA, 99 United States) Collibri ES DNA Library Prep Kit for Illumina (A38607096, ThermoFisher 100 Scientific).

101

102 Analysis of molecular characteristics

103 Sequence data were assembled using the CLC Genomics Workbench Microbial Genomics

104 Module (Qiagen, Venlo, Netherlands). Multilocus sequence type (MLST) was determined using

105 PubMLST (https://pubmlst.org).<sup>9</sup> We determined the SCC*mec* and spa types using

106 SCCmecFinder  $(ver1.2)^{10}$  and spaTyper (software version 1.0 and database version 2023-6-19)<sup>11</sup>

107 on the Center for Genomic Epidemiology website (<u>https://www.genomicepidemiology.org</u>),

108 respectively. Resistance and virulence genes were detected using ResFinder (software version

109	2023-08-22 and database version 2023-04-12) and VirulenceFinder (software version 2.0.3 and
110	database version 2022-12-02) <sup>12,13</sup> on the Center for Genomic Epidemiology website
111	(https://www.genomicepidemiology.org), respectively. Our previous study revealed very similar
112	bacteriological characteristics between ST1-carrying SCCmec type IV (ST1-MRSA-IV) and
113	ST2725-carrying SCCmec type IV (ST2725-MRSA-IV); <sup>5</sup> further, a preliminary investigation as
114	part of the current study showed that ST1-MRSA-IV, ST2725-MRSA-IV, and ST5213-MRSA-
115	IV had the same characteristics. Hence, we combined the data from ST1-MRSA-IV, ST2725-
116	MRSA-IV, and ST5213-MRSA-IV as CC1-MRSA-IV. Core-genome MLST (cgMLST) was
117	performed using Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany. A minimum
118	spanning tree (MST) or unweighted pair group method with arithmetic mean (UPGMA) tree was
119	created based on MLST, cgMLST, and <i>S. aureus</i> accessories using Ridom SeqSphere+ (ver. 9).
120	Samples with more than 10% missing values among the data used for the distance calculation
121	were excluded from constructing the MST or UPGMA. For the UPGMA using strains that were
122	detected during the previous nationwide surveillance, <sup>5</sup> we excluded 13 strains detected at
123	Nagasaki University Hospital to avoid duplication. In UPGMA, a cluster of MRSA strains was
124	classified with a distance of 0.1, and subclusters of ST8 with SCCmec type I (ST8-MRSA-I) and
125	ST8-MRSA-IV, CC1-MRSA-IV, and ST5-MRSA-II were classified with a distance of 0.03.

126

## 127 *Data collection from previous studies*

Data collected during 2003–2007 and 2008–2011 have been reported previously.<sup>4,6</sup> In this study, we compared the new data with the data from the previous study database to confirm the changes in SCC*mec* type and patient characteristics. To match the study period of previous studies with

that of this study, the SCC*mec* type data obtained in this study were analyzed separately for four
years, 2012–2015 and 2016–2019.

133

	134	<i>Statistical</i>	analysis
--	-----	--------------------	----------

- All statistical analyses were performed on GraphPad Prism 10 (version 10.1.0; GraphPad
- 136 Software, Boston, MA, United States of America). Continuous variables were expressed as mean
- $\pm$  standard deviation. Categorical variables were compared using Fisher's exact test, and q values
- 138 were calculated using the Benjamini–Hochberg method for multiple comparisons. Continuous
- 139 variables were compared using Student's t-test for two-group comparisons and Tukey's test for
- 140 multiple comparisons. The statistical significance level was set at p < 0.05 and q < 0.05, and the
- 141 *p*-value was considered not significant (n.s.) if it was greater than 0.2.

142

- 143 *Ethics*
- 144 This study was approved by the Ethics Committee of the Nagasaki University Hospital

145 (20072018). MRSA strains collected from blood cultures were anonymized and individually

146 numbered. Patient information collected from the medical records was also anonymized and

147 individually numbered when. The Ethics Committee of Nagasaki University Hospital waived the

- 148 requirement for informed consent.
- 149
- 150 Results
- 151 *Changes in SCCmec type from 2003 to 2019*

152 Twenty-seven and fifty-eight MRSA strains were isolated during 2012–2015 and 2016–2019,

respectively. The percentages of SCCmec types I, II, and IV during 2012–2015 were 37.0%,

154	37.0%, and 25.9%, respectively. The percentages of SCCmec types I, II, IV, and V during 2016-
155	2019 were 15.5%, 15.5%, 65.5%, and 3.4%, respectively. Fig. 1 and Supplementary Table 1
156	show the changes in SCCmec type from 2003 to 2019. SCCmec type II was the most frequently
157	detected type from 2003 to 2015. However, its frequency decreased significantly from 79.2%
158	during 2003–2007 to 15.5% during 2016–2019 ( $q < 0.001$ ). In contrast, the percentage of
159	SCCmec type IV increased dramatically from 18.2% during 2003–2007 to 65.5% during 2016–
160	2019 ( $q < 0.001$ ). SCCmec type I showed changes that differed from those of SCCmec types II
161	and IV. The percentage of SCCmec type I cases increased significantly from 2.6% during 2003-
162	2007 to 37.0% during 2012–2015 ( $q < 0.001$ ). SCCmec type I was one of the most frequently
163	detected SCCmec types from 2012 to 2015; however, its prevalence decreased by more than 50%
164	(15.5 %) during 2016–2019.

165

## 166 *Changes in patient characteristics from 2003 to 2019*

167 Table 1 and Supplementary Table 1 show the characteristics of patients in each study period. 168 There were no significant differences in the patients' backgrounds, such as age, sex, or 169 underlying diseases, except for the classification of infection; the percentage of healthcare-170 associated infections was significantly higher during 2012-2015 than during 2008-2011 (3.6% 171 vs. 22.2%, q = 0.020). Further, the sources of MRSA infection changed from 2003 to 2019. The 172 percentage of intravascular device-related BSI increased significantly from 18.1% during 2003– 2007 to 46.6% during 2016–2019 (q = 0.002). In contrast, the percentage of respiratory tract 173 174 infection-related BSI significantly decreased from 16.9% during 2003–2007 to 20.5% during 175 2008-2011 and 1.7% during 2016-2019 (*q* = 0.013 and 0.004, respectively). The severity of BSI 176 also changed between 2003 and 2019. SOFA score significantly decreased from  $5.8 \pm 0.5$  during

177	2003–2007 to 3.1 $\pm$ 0.5 during 2016–2019 ( $p$ = 0.004), and accordingly, the in-hospital mortality
178	improved from 39.8% during 2003–2007 to 15.5% during 2016–2019 (q = 0.015).
179	
180	MRSA types based on ST and SCCmec type during 2012–2019
181	The predominant combination of ST and SCCmec types during 2012–2019 was ST8-MRSA-
182	IV (37.6%), followed by ST8-MRSA-I (22.4%), ST5-MRSA-II) (18.8%), and CC1-MRSA-IV
183	(9.4%) (Fig. 1A). The changes in the major combinations are shown in Fig. 2B and
184	Supplementary Table 2. Although there was no change in the percentage of ST8 between 2012–
185	2015 and 2016–2019, the combination of SCCmec type with ST8 differed between the two
186	periods. The percentage of ST8-MRSA-IV was significantly higher during 2016–2019 (44.8%)
187	than during 2012–2015 (22.2%). In contrast, the percentage of ST8-MRSA-I was significantly
188	lower during 2016–2019 (15.5%) than during 2012–2015 (37.0%; <i>p</i> = 0.048).
189	
190	Patient characteristics and drug-resistance rate in the major MRSA types
191	Table 2 and Supplementary Table 3 show the patient characteristics for each major
192	
	combination. No significant differences were observed with respect to the patient characteristics
193	combination. No significant differences were observed with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1-
193 194	combination. No significant differences were observed with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1- MRSA-IV, with $2.3 \pm 0.6$ and $12.5\%$ , respectively than those of other major MRSA types;
193 194 195	combination. No significant differences were observed with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1- MRSA-IV, with $2.3 \pm 0.6$ and $12.5\%$ , respectively than those of other major MRSA types; however, there was no statistical difference.
193 194 195 196	<ul> <li>combination. No significant differences were observed with respect to the patient characteristics</li> <li>among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1-</li> <li>MRSA-IV, with 2.3 ± 0.6 and 12.5%, respectively than those of other major MRSA types;</li> <li>however, there was no statistical difference.</li> <li>The drug-resistance rates of the major MRSA types to different antimicrobial agents are</li> </ul>
193 194 195 196 197	<ul> <li>combination. No significant differences were observed with respect to the patient characteristics</li> <li>among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1-</li> <li>MRSA-IV, with 2.3 ± 0.6 and 12.5%, respectively than those of other major MRSA types;</li> <li>however, there was no statistical difference.</li> <li>The drug-resistance rates of the major MRSA types to different antimicrobial agents are</li> <li>shown in Table 2 and Supplementary Table 3. The levofloxacin resistance rate was significantly</li> </ul>
193 194 195 196 197 198	<ul> <li>combination. No significant differences were observed with respect to the patient characteristics</li> <li>among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1-</li> <li>MRSA-IV, with 2.3 ± 0.6 and 12.5%, respectively than those of other major MRSA types;</li> <li>however, there was no statistical difference.</li> <li>The drug-resistance rates of the major MRSA types to different antimicrobial agents are</li> <li>shown in Table 2 and Supplementary Table 3. The levofloxacin resistance rate was significantly</li> <li>lower in ST8-MRSA-IV than in all the other major MRSA types (q = 0.002 vs. ST8-MRSA-I</li> </ul>
193 194 195 196 197 198 199	combination. No significant differences were observed with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1- MRSA-IV, with $2.3 \pm 0.6$ and $12.5\%$ , respectively than those of other major MRSA types; however, there was no statistical difference. The drug-resistance rates of the major MRSA types to different antimicrobial agents are shown in Table 2 and Supplementary Table 3. The levofloxacin resistance rate was significantly lower in ST8-MRSA-IV than in all the other major MRSA types ( $q = 0.002$ vs. ST8-MRSA-I and ST5-MRSA-II and $q = 0.032$ vs. CC1-MRSA-IV). The erythromycin resistance rate was also

200	significantly lower in ST8-MRSA-IV than in ST8-MRSA-I. In contrast, the clindamycin
201	resistance rate of ST5-MRSA-II was significantly higher than that of all other major MRSA
202	types ( $q < 0.001$ for all comparisons). CLSI and EUCAST guidelines differ in their protocols for
203	determining minocycline resistance rates. All strains were sensitive to minocycline per the CLSI
204	guidelines; however, when tested according to the EUCAST guidelines, a difference in
205	minocycline resistance rates was observed among the major MRSA types. The minocycline
206	resistance rate was significantly higher in ST8-MRSA-I and ST5-MRSA-II than in ST8-MRSA-
207	IV and CC1-MRSA-IV. There were also differences in the MICs of beta-lactams, for which the
208	CLSI or EUCAST did not set breakpoints for MRSA. The MICs of cefazolin, imipenem, and
209	meropenem were lower for ST8-MRSA-IV and CC1-MRSA-IV than for ST8-MRSA-I and ST5-
210	MRSA-II (Supplementary Fig. 1C-F). The MICs of imipenem against most strains belonging to
211	the ST8-MRSA-IV and CC1-MRSA-IV were less than 0.5, in contrast to those of the ST8-
212	MRSA-I and ST5-MRSA-II, which were higher than 16 (Supplementary Fig. 1E).
213	
214	Molecular characteristics of the strains in the major MRSA types
215	Drug resistance and virulence genes differed among the major MRSA types. Although ST8-
216	MRSA-IV and ST8-MRSA-I belonged to the same sequence type, the positivity rates for drug-
217	resistance genes, such as aadD, ant(9)-Ia, erm(A), tet(M), and bleO, in ST8-MRSA-I were

significantly higher than those in ST8-MRSA-IV (Fig. 3A). ST8-MRSA-I showed a similar trend

219 with respect to its drug-resistance genes as that demonstrated by ST5-MRSA-II, except for

aac(6')-aph(2''). However, the positivity rates for the virulence genes differed between ST8-

221 MRSA-I and ST5-MRSA-II. The positivity rates for sec, seg, sei, sel, sem, seo, sep, seu, and tst

222 were significantly higher in ST5-MRSA-II than in ST8-MRSA-I. In contrast, the positivity rate

- for *splE* was significantly lower in ST5-MRSA-II than that in ST8-MRSA-I (Fig. 3B). CC1-
- 224 MRSA-IV has characteristic virulence gene features. It harbors virulence genes such as *sea*, *seh*,
- sek, and seq, which are absent in other major MRSA types.
- In ST8-MRSA-IV, the positivity rates for drug-resistance and virulence genes, such as aac(6')-
- 227 *aph*(2''), *aadD*, *ant*(9)-*Ia*, *erm*(A), *bleO*, *sec*, *sel*, *sep*, *tst*, and *splE*, were around 50% (Fig. 3).
- 228 Phylogenetic analysis based on core genome MLST revealed that ST8-MRSA-IV was divided
- into several clusters (Supplementary Fig. 2). Based on the results of the virulence genes sec and
- 230 *tst* and the *spa* type,  $^{5}$  14 and 4 strains were classified as CA-MRSA/J and t5071-ST8-MRSA-IV,
- 231 respectively. There were significant differences between CA-MRSA/J and t5071-ST8-MRSA-IV
- gene expression (Supplementary Table 4). The positive rates for *aac*(6')-*aph*(2''), *aadD*, *bleO*,
- 233 sec, sel, and tst were significantly higher in CA-MRSA/J than in t5071-ST8-MRSA-IV (p < 1
- 234 0.05), and those for *ant*(9)-*Ia*, *erm*(*A*), *splE*, and *sep* were significantly lower in CA-MRSA/J
- than in t5071-ST8-MRSA-IV (p < 0.05). Based on antimicrobial susceptibility testing, CA-
- 236 MRSA/J was more sensitive to levofloxacin, erythromycin, clindamycin, and minocycline than
- 237 was t5071-ST8-MRSA-IV (p < 0.05) (Supplementary Table 4).
- 238
- 239 Relationship between the strains detected in Nagasaki and those circulating in Japan

Phylogenetic tree analysis based on MLST, cgMLST, and *S. aureus* accessory sequences was
performed to investigate the relationship between the strains detected in this study and those
from the previous nationwide surveillance.<sup>5</sup> Based on the phylogenetic tree analysis, the strains

- 243 were divided into three major clusters, ST8-MRSA-IV and ST8-MRSA-I, CC1-MRSA-IV, and
- 244 ST5-MRSA-II (Supplementary Fig. 3). In the ST8-MRSA-IV and ST8-MRSA-I clusters (Fig.
- 245 4A), most ST8-MRSA-I strains detected in Nagasaki and the nationwide surveillance were

246	classified into subcluster 3, whereas ST8-MRSA-IV was divided into ten subgroups. However,
247	in the ST8-MRSA-IV group, all CA-MRSA/J strains detected in Nagasaki and nationwide were
248	classified into subcluster 1. All t5071-ST8-MRSA-IV strains detected in Nagasaki and
249	nationwide were classified into subcluster 5. The ST5-MRSA-II strains showed the same trend as
250	that of the ST8-MRSA-IV strains. The ST5-MRSA-II strains detected in Nagasaki were divided
251	into five subclusters (Fig. 4C). In contrast to ST8-MRSA-IV and ST5-MRSA-II, most CC1-
252	MRSA-IV strains detected in Nagasaki and nationwide surveillance were classified into the same
253	sub-cluster 12 (Fig. 4B).
254	
255	Discussion
256	This study revealed that SCCmec type IV has quickly become the predominant SCCmec type
257	and replaced SCCmec type II since the mid-2010s in patients with BSIs. In the United States,
258	SCCmec type IV has increased in prevalence and replaced SCCmec type II in BSIs since the late

259 2000s.[8] Based on the results from the two nationwide surveillance conducted in Japan, the

260 prevalence of SCCmec type IV increased from 19.9% in 2011 to 77.4% in 2019, whereas that of

261 SCCmec type II decreased to 7.8% in 2019 from 75.6% in 2011.[5,9] In addition, according to a

262 previous Japanese study conducted in the Kanto region, the prevalence of SCCmec type IV was

263 higher than that of SCCmec type II in 2016,[10] which is similar to the results of this study.

264 These results indicate that the shift from SCCmec type II to IV occurred almost simultaneously

265 throughout Japan in the mid-2010s.

266 Although SCCmec type IV is the predominant SCCmec type in both the United States and

267 Japan, its molecular characteristics differ. The USA300-like clone (t008-ST8-MRSA-IV) was the

most common MRSA type in the United States.[8] However, the percentage of the clone was 268

269	only 3.3% in Japan in 2019, <sup>5</sup> which is similar to the results of this study. In Japan, two
270	significant types of ST8-MRSA-IV circulate: CA-MRSA/J and t5071-ST8-MRSA-IV. <sup>5</sup> In this
271	study, although CA-MRSA/J was the predominant strain of ST8-MRSA-IV, t5071-ST8-MRSA-
272	IV was not frequently detected. This was unsurprising because t5071-ST8-MRSA-IV was
273	primarily detected in the Kinki region. <sup>5</sup> Another feature that differed between the United States
274	and Japan was the higher prevalence of CC1-MRSA-IV than ST8-MRSA-IV in Japan, <sup>5</sup> although
275	there were regional differences in the ratios of CC1-MRSA-IV and ST8-MRSA-IV in Japan: the
276	percentage of ST8-MRSA-IV was much higher than that of CC1-MRSA-IV in western Japan,
277	including the Kyushu region, where Nagasaki belongs. <sup>5</sup> However, in a single-center study
278	conducted in the Kyushu region during 2018–2019, the percentage of CC1-MRSA-IV was
279	14.2% in blood cultures, whereas, it was 59.0% and 77.3% in sputum and skin and soft tissues,
280	respectively.[12] In addition, a previous study conducted in Hokkaido reported a rapidly
281	increasing percentage of CC1-MRSA-IV in BSIs in 2019. <sup>18</sup> Considering that CC1-MRSA-IV
282	was detected only after 2016 in this study, it is possible that we only observed the early stages of
283	CC1-MRSA-IV circulation in our region.
284	The CA-MRSA/J, t5071-ST8-MRSA-IV, and CC1-MRSA-IV types detected in Nagasaki and
285	nationwide surveillance <sup>5</sup> were classified into the same subcluster during phylogenetic analysis.
286	The drug susceptibility characteristic trends in our study were similar to those in the national

surveillance<sup>5</sup> for most cases. In both studies, the following differences among the major types

288 were observed. CA-MRSA/J was sensitive to levofloxacin; CA-MRSA/J and CC1-MRSA-IV

were sensitive to clindamycin, while t5071-ST8-MRSA-IV was resistant; for minocycline, all

290 types were sensitive according to CLSI criteria, whereas t5071-ST8-MRSA-IV had a very high

rate of resistance according to the EUCAST criteria. The positivity rates for drug-resistance

292	genes showed the same trends in both studies. Almost all CC1-MRSA-IV and t5071-ST8-
293	MRSA-IV harbored $ant(9)$ -Ia and $erm$ (A). In contrast, the positivity rates for $aac(6')$ - $aph(2'')$
294	and <i>aadD</i> were much higher in CA-MRSA/J than in other types. The positivity rates for
295	virulence genes showed the same trend in both studies. The virulence genes sea, seh, sek, and seq
296	were harbored by the CC1-MRSA-IV but not the other two types. Similarly, CA-MRSA/J, but
297	not the other two types, harbored sec, sel, and tst. In contrast, CA-MRSA/J did not harbor splE.
298	These results suggest that CA-MRSA/J, t5071-ST8-MRSA-IV, and CC1-MRSA-IV have spread
299	across the nation rapidly with the same molecular background and characteristics.
300	The present study also observed trends differing from nationwide surveillance. In our hospital,
301	the prevalence of SCCmec type I increased from 2003 to 2015 and became the predominant
302	MRSA type during 2012-2015. Unlike the ST8-MRSA-IV, ST8-MRSA-I showed a similar trend
303	to that of ST5-MRSA-II in drug resistance. The difference from ST5-MRSA-II was that ST8-
304	MRSA-I was more sensitive to clindamycin and exhibited higher positivity rates for $aac(6')$ -
305	aph(2') and $aadD$ . In contrast, their virulence genes were completely different, with ST8-
306	MRSA-I having markedly fewer virulence factors than ST5-MRSA-II. In virulence genes, ST8-
307	MRSA-I showed a trend similar to that of t5071-ST8-MRSA-IV; however, sed, sej, and ser were
308	detected only in ST8-MRSA-I. In the nationwide surveillance study, four ST8-MRSA-I strains
309	were detected in the Kyushu region. <sup>5</sup> In a previous single-center study in the Kyushu region,
310	ST8-MRSA-I was the second most frequently detected type during 2018–2019.[12] Additionally,
311	several studies in the Kyushu region detected a certain percentage of SCCmec type I strains.[13–
312	15] These results indicated that ST8-MRSA-I spread independently in the Kyushu region.
313	In the current study, we investigated the changes in patient characteristics. Although patient
314	backgrounds did not change between 2003 and 2019, SOFA scores and in-hospital mortality

315	improved significantly. In addition, the source of MRSA infection has changed. The percentage
316	of patients with intravascular device-related BSI was much higher during 2016–2019 than during
317	2003–2007, whereas that of patients with respiratory tract infections was much lower during
318	2016–2019 than during 2003–2007. We also compared the patient characteristics among the
319	major MRSA types. The SOFA score and in-hospital mortality in patients with the ST5-MRSA-
320	II were higher than those with ST8-MRSA-IV, ST8-MRSA-I, or CC1-MRSA-IV types. In
321	addition, the percentage of patients with respiratory tract infections was higher in ST5-MRSA-II
322	than in ST8-MRSA-IV, ST8-MRSA-I, and CC1-MRSA-IV. In contrast, the initial anti-MRSA
323	treatment did not differ considerably based on the MRSA types. Because the prevalence of ST5-
324	MRSA-II decreased and those of ST8-MRSA-IV and CC1-MRSA-IV increased from 2003 to
325	2019, and there was no change in patient background, the changes in MRSA types may have
326	reduced the severity and in-hospital mortality.
327	This study has several limitations. First, because this was a single-center study, it is unclear
328	whether the differences in patient characteristics for each MRSA type can be generalized.
329	Second, to reduce the likelihood of contamination, we included only cases that were positive for
330	at least two sets of blood cultures. This inclusion criterion is the same as that used in the
331	nationwide surveillance <sup>5</sup> but different from that used in our previous studies. <sup>4,6</sup> Third, there were
332	several strains for which the spa type was not determined or excluded from the phylogenetic
333	analysis: 22 of 85 strains (25.9%) and 10 of 75 strains (13.3%), respectively. This is a limitation
334	that also holds true for nationwide surveillance. <sup>5</sup>
335	In conclusion, this study demonstrated that the major MRSA types in BSIs changed over time

and were associated with reduced disease severity and in-hospital mortality. In addition, changes

337	in the major	MRSA types	were directly	influenced by	changes in	the circulating strains
-----	--------------	------------	---------------	---------------	------------	-------------------------

- antionally and regionally.
- 339

## 340 Data availability

- Raw data were generated at the Nagasaki University Hospital. The derived data supporting the
- 342 findings of this study are presented in the paper and supplementary tables and figures. The WGS
- 343 data reported in this study are available in the NCBI Sequence Read Archive
- 344 (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA1065106. WGS data
- from the previous nationwide surveillance<sup>5</sup> are available in the DDBJ Sequence Read Archive
- 346 (<u>https://www.ddbj.nig.ac.jp/dra/index-e.html</u>) under the accession number DRA013058.

347

### 348 **Conflicts of interest**

349 The authors have no conflicts to declare.

350

**Funding:** This work was supported by the Japanese Association for Infectious Diseases (The 1<sup>st</sup>

352 Grant for Clinical Research Promotion, 2018) and the Japanese Antibiotics Research Association

353 (The 23<sup>rd</sup> Encouragement Award, 2021). The funders had no role in the data analysis or the

decision to publish.

355

#### **356** Author contributions

- 357 N. K. and K. Y. designed the experiments. N. K., M. I., G. Y., and D. S. acquired the data. N.K.,
- 358 K.O., F. M. K., K.K., H.H., K.I., H.M., and K.Y. analyzed the data. N.K. wrote the manuscript.
- 359 All the authors have revised and approved the manuscript for publication.

- 361 Acknowledgments: We thank Mr. Shuji Miyazaki (Department of Laboratory Medicine,
- 362 Nagasaki University of Hospital) for supporting the analysis of MRSA strains. We would like to
- thank Editage (<u>www.editage.jp</u>) for editing the English language.
- 364

# 365 **References**

- 3661Tsuzuki S, Matsunaga N, Yahara K, Shibayama K, Sugai M, Ohmagari N. Disease burden of367bloodstream infections caused by antimicrobial-resistant bacteria: A population-level368aturdu lange 2015, 2018, International Journal of Infectious Diseases 2021; 109: 110, 124
- 368 study, Japan, 2015–2018. *International Journal of Infectious Diseases* 2021; **108**: 119–124.
- Kern W V., Rieg S. Burden of bacterial bloodstream infection-a brief update on
  epidemiology and significance of multidrug-resistant pathogens. *Clin Microbiol Infect*2020; **26**: 151–157.
- 372 3 Yamamoto T *et al.* Community-acquired methicillin-resistant Staphylococcus aureus:
   373 community transmission, pathogenesis, and drug resistance. *Journal of Infection and* 374 *Chemotherapy* 2010; **16**: 225–254.
- 3754Kaku N *et al.* Influence of antimicrobial regimen on decreased in-hospital mortality of376patients with MRSA bacteremia. Journal of Infection and Chemotherapy 2014; **20**: 350–377355.
- Kaku N, Sasaki D, Ota K, Miyazaki T, Yanagihara K. Changing molecular epidemiology and
  characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in
  Japan in 2019. *J Antimicrob Chemother* 2022; **77**: 2130–2141.
- Motoshima M *et al.* Genetic diagnosis of community-acquired MRSA: a multiplex realtime PCR method for Staphylococcal cassette chromosome mec typing and detecting
  toxin genes. *Tohoku J Exp Med* 2010; **220**: 165–170.
- Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity
   index. J Clin Epidemiol 1994; 47: 1245–1251.
- 3868Singer M et al. The Third International Consensus Definitions for Sepsis and Septic Shock387(Sepsis-3). JAMA 2016; **315**: 801–810.
- Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb
   software, the PubMLST.org website and their applications [version 1; referees: 2
- 390 approved]. *Wellcome Open Res* 2018; **3**. doi:10.12688/WELLCOMEOPENRES.14826.1/DOI.
- Kaya H *et al.* SCC mec Finder, a Web-Based Tool for Typing of Staphylococcal Cassette
   Chromosome mec in Staphylococcus aureus Using Whole-Genome Sequence Data.
   *mSphere* 2018; **3**: e00612-17.
- Bartels MD *et al.* Comparing whole-genome sequencing with Sanger sequencing for spa
   typing of methicillin-resistant Staphylococcus aureus. *J Clin Microbiol* 2014; **52**: 4305–
   4308.

397 Tetzschner AMM, Johnson JR, Johnston BD, Lund O, Scheutz F. In Silico Genotyping of 12 398 Escherichia coli Isolates for Extraintestinal Virulence Genes by Use of Whole-Genome 399 Sequencing Data. J Clin Microbiol 2020; 58. doi:10.1128/JCM.01269-20. 400 Joensen KG *et al.* Real-time whole-genome sequencing for routine typing, surveillance, 13 401 and outbreak detection of verotoxigenic Escherichia coli. J Clin Microbiol 2014; 52: 1501-402 1510. 403 14 Tickler IA, Goering R V., Mediavilla JR, Kreiswirth BN, Tenover FC. Continued expansion of 404 USA300-like methicillin-resistant Staphylococcus aureus (MRSA) among hospitalized 405 patients in the United States. *Diagn Microbiol Infect Dis* 2017; 88: 342–347. 406 15 Miura Y et al. Epidemiological Trends Observed from Molecular Characterization of 407 Methicillin-Resistant Staphylococcus aureus Isolates from Blood Cultures at a Japanese 408 University Hospital, 2012–2015. Microbial Drug Resistance 2018; 24: 70–75. 409 16 Hamada M et al. Increased Incidence and Plasma-Biofilm Formation Ability of SCC mec 410 Type IV Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated From Patients With Bacteremia. Front Cell Infect Microbiol 2021; 11. doi:10.3389/FCIMB.2021.602833. 411 412 17 Mitsumoto-Kaseida F et al. The clinical characteristics and molecular epidemiology of 413 methicillin-resistant Staphylococcus aureus (MRSA) among very elderly people in Japan. 414 Geriatr Gerontol Int 2023; 23: 744–749. 415 Aung MS et al. Molecular Epidemiological Characterization of Methicillin-Resistant 18 Staphylococcus aureus from Bloodstream Infections in Northern Japan: Increasing Trend 416 of CC1 and Identification of ST8-SCCmec IVa USA300-Like Isolate Lacking Arginine 417 418 Catabolic Mobile Element. doi:10.1089/mdr.2023.0203. 419 19 Kimura Y et al. Antimicrobial susceptibility and molecular characteristics of methicillin-420 resistant Staphylococcus aureus in a Japanese secondary care facility. Journal of Infection 421 and Chemotherapy 2016; 22: 14-18. 422 20 Nakano Y et al. Clinical characteristics and factors related to infection with SCC mec type 423 II and IV Methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility: 424 a single-center retrospective study. J Glob Antimicrob Resist 2022; **31**: 355–362. 425 21 Mitsumoto-Kaseida F et al. Clinical and pathogenic features of SCCmec type II and IV 426 methicillin-resistant Staphylococcus aureus in Japan. Journal of Infection and 427 Chemotherapy 2017; 23: 90–95. 428

# 430 Tables

# Table 1. Changes in patient characteristics from 2003 to 2019

	2003-2007	2008-2011	2012-2015	2016-2019
	n = 83	n = 83	n = 27	n = 58
Age, average	$63.7\pm1.9$	$67.3 \pm 1.6$	$69.1\pm3.2$	$63.4\pm3.2$
Sex, female	47.0%	30.1%	25.9%	36.2%
Charlson comorbidity index	$3.0\pm0.2$	$3.1 \pm 0.2$	$4.0\pm0.5$	$3.2\pm0.3$
Number of days of				
hospitalization after MRSA	No data	$41.9\pm6.3$	$38.5\pm6.3$	$36.1\pm7.9$
detection				
Antimicrobial use during the 30	NT 1.4	75.00/	50.20/	<b>CD 20</b> /
days before MRSA detection	No data	/5.9%	59.3%	60.3%
Classification of infection				
Community-acquired	No data	3.6%	-	8.6%
Healthcare-associated	No data	3.6%	22.2%	13.8%
Hospital-acquired	No data	86.7%	77.8%	77.6%
Source of MRSA infection				
Intravascular device	18.1%	30.1%	29.6%	46.6%
Respiratory tract	16.9%	20.5%	11.1%	1.7%
Skin/soft tissue or surgical site	10.8%	15.7%	25.9%	13.8%
Abdomen	7.2%	4.8%	-	8.6%
Bone and joint	13.3%	2.4%	11.1%	8.6%
Others	7.2%	6.0%	11.1%	3.4%

Unknown	26.5%	20.5%	11.1%	17.2%	
SOFA score	$5.8\pm0.5$	$5.8\pm0.5$	$4.2\pm0.9$	$3.1\pm0.4$	
Initial antimicrobial chemotherapy against MRSA					
Vancomycin	28.9%	45.8%	55.6%	69.0%	
Teicoplanin	39.8%	13.3%	11.1%	5.2%	
Linezolid	10.8%	21.7%	25.9%	1.7%	
Daptomycin	-	-	11.1%	20.7%	
Arbekacin	3.6%	1.2%	-	-	
No anti-MRSA agents	16.9%	19.3%	-	5.2%	
Change of initial treatment	34.9%	30.1%	25.9%	37.9%	
In-hospital mortality	39.8%	25.3%	37.0%	15.5%	
30-day mortality	No data	18.1%	18.5%	10.3%	

431

# Table 2. Patient characteristics and drug-resistance rates according to the major MRSA

## types

	ST8-MRSA-	ST8-MRSA-I	ST5-MRSA-II	CC1-MRSA-
				IV
	n = 32	n = 19	n = 16	n = 8
Age, average	$67.4 \pm 3.9$	$65.6 \pm 5.4$	63.5 ± 5.3	$68.1 \pm 4.3$
Sex, female	34.4%	21.1%	43.8%	62.5%
Charlson comorbidity index	$3.1 \pm 0.5$	$4.8\pm0.7$	$3.1\pm0.5$	$3.0\pm0.8$
Number of hospitalization days after MRSA detection	$40.2 \pm 8.1$	$32.6 \pm 7.0$	$57.8\pm26.9$	48.1 ± 12.1
Antimicrobial use during the 30 days before MRSA detection	62.5%	47.4%	68.8%	62.5%
Classification of infection				
Community-acquired	6.3%	5.3%	6.3%	-
Healthcare-associated	12.5%	21.1%	12.5%	-
Hospital-acquired	81.3%	73.7%	81.3%	100%
Source of MRSA infection				
Intravascular device	40.6%	47.4%	43.8%	25.0%
Respiratory tract	-	5.3%	18.8%	-
Skin/soft tissue or surgical site	21.9%	10.5%	12.6%	12.5%
Abdomen	6.3%	5.3%	6.3%	12.5%
Bone and joint	6.3%	15.8%	6.3%	-
Others	3.1%	10.5%	6.3%	12.5%

Unknown	21.9%	5.35	6.3%	37.5%
SOFA score	$3.4\pm0.7$	$3.5\pm0.9$	$4.4 \pm 1.1$	$2.3\pm0.6$
Initial antimicrobial chemotherap	y against MRSA			
Vancomycin	68.8%	62.3%	62.5%	62.5%
Teicoplanin	6.3%	5.3%	6.3%	12.5%
Linezolid	9.4%	15.8%	12.5%	-
Daptomycin	18.8%	15.8%	18.8%	12.5%
No anti-MRSA agents	-	5.3%	-	12.5%
Change of initial treatment	43.8%	31.6%	37.5%	25.0%
In-hospital mortality	21.9%	26.3%	31.3%	12.5%
30-day mortality	12.5%	10.5%	25.0%	12.5%

Drug resistance rates according to CLSI/EUCAST guidelines

Oxacillin	96.9% / 96.9%	100% / 100%	100% / 100%	87.5% / 87.5%
Cefoxitin	100% / 100%	100% / 100%	100% / 100%	100% / 100%
Levofloxacin	53.1% / 53.1%	100% / 100%	100% / 100%	100% / 100%
Erythromycin	68.8% / 71.9%	100% / 100%	100% / 100%	87.5% / 87.5%
Clindamycin	28.1% / 31.3%	36.8% / 36.8%	100% / 100%	25.0% / 25.0%
Minocycline	0% / 21.9%	0% / 89.5%	0% / 68.8%	0% / 12.5%
Vancomycin	0% / 0%	0% / 0%	0% / 0%	0% / 0%
Teicoplanin	0% / 0%	0% / 0%	0% / 0%	0% / 0%
Linezolid	0% / 0%	5.3% / 5.3%	6.3% / 6.3%	0% / 0%

433

## 435 Figure legends

### 436 Fig. 1. Changes in SCCmec type

- 437 Changes in SCCmec type from 2003 to 2019 were evaluated. Data regarding SCCmec type
- during 2003–2007 and 2008–2011 have been reported previously. The inclusion criteria for
- 439 MRSA strains in this study (2012–2015 and 2016–2019) differed from those used in previous
- 440 studies (2003–2007 and 2008–2011). In previous studies, MRSA strains collected from one or
- 441 more blood cultures were analyzed, whereas in this study, MRSA strains collected from two or
- 442 more blood cultures were analyzed.

## 443 Fig. 2. Major MRSA types based on sequence type and SCCmec type

- 444 SCC*mec* type and sequence type (ST) from 2012 to 2019 were evaluated (A). The changes in the
- 445 percentage of major MRSA types based on the SCCmec type and ST from 2012 to 2019 was also
- 446 evaluated (**B**). We decided on ST based on whole-genome sequencing using the CLC Genomics
- 447 Workbench and the CLC Microbial Genomics Module (Qiagen, Venlo, Netherlands).

448 Fig. 3. The positivity rates for drug-resistance and virulence genes in the major MRSA

449 **types** 

450 Drug-resistance (A) and virulence (B) genes were detected after whole-genome sequencing using

451 ResFinder and virulence finder, respectively.

452 Fig. 4. Phylogenetic analysis of MRSA strains detected in Nagasaki and those circulating in
453 Japan

- 454 Phylogenetic tree analysis was performed based on MLST, core genome MLST (cgMLST), and
- 455 *S. aureus* accessory sequences to investigate the relationship between the strains detected in this
- 456 study and those from the previous nationwide surveillance. Based on the phylogenetic tree
- 457 analysis of all strains (Supplementary Fig. 3), the strains were divided into three major clusters:

- 458 ST8-MRSA-IV and ST8-MRSA-I (A), CC1-MRSA-IV (B), and ST5-MRSA-II (C). cgMLST
- 459 was performed using the Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany). A
- 460 UPGMA tree was created based on MLST, cgMLST, and *S. aureus* accessory genes. Samples
- 461 with more than 10% missing values among the data used for distance calculation were excluded.
- 462 During UPGMA of the strains detected during the previous nationwide surveillance, the strains
- 463 detected at Nagasaki University Hospital were excluded to avoid duplication.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



# Fig. 1. Changes in SCCmec type

Changes in SCC*mec* type from 2003 to 2019 were evaluated. Data regarding SCC*mec* type during 2003–2007 and 2008–2011 have been reported previously. The inclusion criteria for MRSA strains in this study (2012–2015 and 2016–2019) differed from those used in previous studies (2003–2007 and 2008–2011). In previous studies, MRSA strains collected from one or more blood cultures were analyzed, whereas in this study, MRSA strains collected from two or more blood cultures were analyzed.



## Fig. 2. Major MRSA types based on sequence type and SCCmec type

SCC*mec* type and sequence type (ST) from 2012 to 2019 were evaluated (A). The changes in the percentage of major MRSA types based on the SCC*mec* type and ST from 2012 to 2019 was also evaluated (**B**). We decided on ST based on whole-genome sequencing using the CLC Genomics Workbench and the CLC Microbial Genomics Module (Qiagen, Venlo, Netherlands).



Fig. 3. The positivity rates for drug-resistance and virulence genes in the major MRSA types

Drug-resistance (A) and virulence (B) genes were detected after whole-genome sequencing using ResFinder and virulence finder, respectively.



(A)



Fig. 4. Phylogenetic analysis of MRSA strains detected in Nagasaki and those circulating in Japan Phylogenetic tree analysis was performed based on MLST, core genome MLST (cgMLST), and *S. aureus* accessory sequences to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance. Based on the phylogenetic tree analysis of all strains (Supplementary Fig. 3), the strains were divided into three major clusters: ST8-MRSA-IV and ST8-MRSA-I (A), CC1-MRSA-IV (B), and ST5-MRSA-II (C). cgMLST was performed using the Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany). A UPGMA tree was created based on MLST, cgMLST, and *S. aureus* accessory genes. Samples with more than 10% missing values among the data used for distance calculation were excluded. During UPGMA of the strains detected during the previous nationwide surveillance, the strains detected at Nagasaki University Hospital were excluded to avoid duplication.